34 results about "Angioedema" patented technology

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.

RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.

The invention discloses a diamine cyclopentane compound, a composition and application of the diamine cyclopentane compound, and belongs to the field of chemical medicines. The invention provides a diamine cyclopentane compound as shown in formula (I), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotope variant thereof, and the diamine cyclopentane compound can be used for preventing and inhibiting neurogenic inflammation, and is used for treating and / or preventing urticaria itching, angioedema and other related diseases. # imgabs0 #

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Described herein is a method of administering injectable cetirizine or levocetirizine to treat acute urticaria, with or without concomitant angioedema, without life-threatening airway swelling by intravenously injecting a human patient within minutes to hours of developing acute urticaria in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition. In the method, the injectable cetirizine or levocetirizine is the only treatment administered in the emergency department or clinic. The method can include determining, by the patient, a patient rated pruritus severity score at a 1 hour assessment, and optionally at a 2 hours assessment, and a physician discharging the human patient after 1.7±0.9 hours in the emergency department or clinic, wherein the human patient has a patient rated pruritus severity score reduction of at least 1 unit and baseline sedation at the time of discharge.

The invention discloses a diamino tetrahydropyran compound, a composition and application of the diamino tetrahydropyran compound, and belongs to the field of chemical medicines. The invention provides a diamine tetrahydropyran compound as shown in a formula (I), or pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystal form, stereoisomer or isotope variant thereof, which can be used for preventing and inhibiting neurogenic inflammation, and is used for treating and / or preventing urticaria itching, angioedema and other related diseases.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).

Provided is a diagnostic test for the positive identification of patients with bradykinin-mediated angioedema. The test is valuable for distinguishing bradykinin-mediated angioedema from non-bradykinin-mediated angioedema. The test allows clinicians to clearly separate patients with bradykinin-mediated from histamine-mediated angioedema. Results can be obtained in under an hour, allowing for the proper treatment of angioedema based on the underlying etiology.

The present invention provides a pharmaceutical composition containing azilsartan medoxomil potassium and a calcium channel blocker, as well as a method for preparing and using the same. The development of a combination formulation using azilsartan medoxomil potassium and a calcium channel blocker is advantageous in terms of improving antihypertensive effects, improving safety and tolerability, and reducing side effects. Azilsartan medoxomil potassium can alleviate amlodipine-induced peripheral edema by dilating peripheral venous blood vessels, while amlodipine can alleviate adverse reactions such as angioedema and dry cough caused by azilsartan medoxomil potassium. Compared with single drugs, the advantages of combination drugs include: (1) reducing medication dosage and improving patient compliance; (2) improving compliance for elderly people and those with dysphagia; and (3) preventing frequent fluctuations in blood drug concentrations, maintaining stable blood drug concentrations, stabilizing blood pressure in hypertensive patients over the long term, and reducing the side effects of each drug. (4) Avoid patients discontinuing medication on their own, and prevent disease recurrence and progression of malignant complications.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

To provide methods for treating hereditary angioedema (HAE) attacks or reducing the rate of HAE attacks.SOLUTION: Provided is a composition comprising an antibody capable of binding to and inhibiting active human plasma kallikrein (pKal), the composition being administered such that the antibody is administered to a human subject multiple times at about 300 mg every two weeks during a first treatment period, the human subject having, being suspected of having, or being at risk for HAE, the human subject (i) being female; (ii) being under 18 years of age or between 40 and 65 years of age; (iii) having had at least one previous attack of laryngeal HAE; (iv) having had 1-2, 2-3, or 4 or more attacks of HAE in the four weeks prior to the first administration of the first treatment period; and / or (v) having been treated with a C1-inhibitor prior to the first treatment period.SELECTED DRAWING: Figure 1

The present invention provides pharmaceutical dosage forms in the form of an orodispersible tablet comprising a plasma kallikrein inhibitor, mixtures for use in manufacturing processes for producing the orodispersible tablets of the invention and the uses of such orodispersible tablets. The orodispersible tablets of the present invention are particularly suitable for patients who may struggle to swallow tablets. The present invention provides on-demand treatments of bradykinin-mediated angioedema by orally administering a plasma kallikrein inhibitor to a patient in need thereof in the form of an orodispersible tablet.

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).

The present invention relates to heteroarylcarboxamide compounds and their pharmaceutical uses. Specifically, the present invention relates to heteroarylcarboxamide compounds represented by general formula (I), methods for producing the same, pharmaceutical compositions containing the compound, and their use as therapeutic agents, particularly as plasma kallikrein (PKa) selective inhibitors, and in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, particularly for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal angiogenesis, hereditary angioedema (HAE), and post-stroke cerebral edema. JPEG2026525258000208.jpg2785

The invention relates to a bradykinin (BK) B2-receptor antagonist having structural formula (I) for use in prophylactic treatment of angioedema (AE) or in a method of treating AE, wherein said compound is at least once orally administered in a therapeutically effective dose to prevent, alleviate or treat AE symptoms. This invention also provides a method of prophylactic treatment of a human patient suffering from AE or a method for on-demand treatment of a human patient who has experienced an acute AE attack, comprising orally administering to the human patient a therapeutically effective dose of the compound of formula (I) at least once to thereby alleviate or treat AE symptoms of the patient.

The invention discloses gRNA of targeted kallikrein, a recombinant vector, an RNA delivery system, a gene editing system, a recombinant cell and application of the gRNA, and relates to the technical field of gene editing. The gRNA targeting the kallikrein is designed and screened out, the gRNA has high gene editing efficiency, through gene editing, the level of the kallikrein in cells, tissues, organs and blood can be effectively reduced, and the mRNA level of the coding gene of the kallikrein is reduced. The invention also provides a recombinant vector and a virus particle, and animal experiments prove that the virus particle can reduce vascular permeability and treat hereditary angioedema. The compound has a good effect of preventing and / or treating cardiovascular and cerebrovascular diseases, and has good biological safety, so that the compound has a good application prospect in conveniently treating the cardiovascular and cerebrovascular diseases.

Disclosed herein are formulations of antibodies directed against plasma kallikrein, e.g., anti-plasma kallikrein antibodies. The formulations include, for example, amino acids, sugars, and surfactants. The disclosed formulations are useful for administration to subjects to treat plasma kallikrein associated disorders such as hereditary angioedema (HAE).

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more conditions that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.